- Design
- Systematic review and meta-analysis of randomised trials
- Population
- 22 trials, 28,112 patients after elective total hip arthroplasty
- Primary outcome
- VTE and bleeding
- Effect
- VTE OR 0.62 (95% CI 0.47 to 0.82); bleeding at licensed doses OR 1.06 (0.95 to 1.18)
A meta-analysis pooled 22 randomised trials covering 28,112 patients having elective total hip arthroplasty, comparing direct oral anticoagulants (DOACs) with low molecular weight heparin (LMWH) for VTE prophylaxis.
DOACs were associated with less VTE (OR 0.62, 95% CI 0.47 to 0.82), mainly fewer deep vein thromboses (OR 0.60). Bleeding was slightly higher with DOACs overall (OR 1.19, 1.03 to 1.38), but when the analysis was limited to agents and doses licensed in the UK, there was no difference (OR 1.06, 0.95 to 1.18). Reoperation and mortality did not differ.
The practical message is that a licensed DOAC regimen is at least as safe as LMWH and probably more effective at preventing DVT, while sparing patients weeks of injections. The authors estimate meaningful cost savings for the NHS; whether the same applies in India depends on local drug prices.
Many of the trials predate today's rapid mobilisation protocols, so the absolute benefit in current practice may be smaller. Local guidance still governs the choice, and aspirin-based regimens were not part of this comparison.
- Consider a licensed-dose DOAC as an alternative to LMWH after elective hip replacement.
- Use licensed agents and doses; the bleeding signal appeared with unlicensed regimens.
- The benefit was mainly fewer DVTs; symptomatic events and mortality were not shown to differ.
- Oral dosing may improve adherence over a full prophylaxis course.
- Follow your local protocol; this review did not compare DOACs with aspirin.
Why it matters
Patients may be able to skip weeks of injections without trading clots for bleeds.
Don't overread it
Most of the VTE reduction was in DVT, often asymptomatic; mortality did not differ.
The statistics, in plain English
An odds ratio of 0.62 means about 38% lower odds of VTE with DOACs. The overall bleeding OR of 1.19 was statistically significant, but the licensed-dose subgroup interval (0.95 to 1.18) crossed 1, meaning no clear difference at the doses actually used in practice.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for orthopaedics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free